Endo has reported 14% sales growth in the first quarter of 2020 to $820m, with the company’s generics segment alone seeing turnover up by a similar proportion, 15%, to $251m. The firm said that almost all – around $30m – of the $32m generics rise was driven by “accelerated prescription fulfilment due to consumer access concerns and the utilization of certain generic medications used to treat patients suffering from COVID-19.”
During the first quarter of 2020, Endo’s generics segment launched four products, but saw the benefits of these launches “partially offset by continued